# Aterian, Inc.: financial statements, quarterly

ATER · Nasdaq · CIK 1757715 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ater.md) · [Financials](/companies/ater/financials.md) · [Filings](/companies/ater/filings.md) · [Insiders](/companies/ater/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ater/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [39.7](/filings/0001437749-24-034539.md) | [32.8 d](/filings/0001437749-25-009139.md) | [20.2](/filings/0001437749-25-017173.md) | [28.0](/filings/0001437749-25-026526.md) | [26.2](/filings/0001437749-25-034871.md) | [24.6 d](/filings/0001437749-26-009285.md) | [0.1](/filings/0001437749-26-017437.md) | [0.1](/filings/0001437749-26-028004.md) | [19.0](/filings/0001437749-25-034871.md) | [15.1 d](/filings/0001437749-26-009285.md) | [0.0](/filings/0001437749-26-017437.md) | [0.0](/filings/0001437749-26-028004.md) |
| Cost of revenue | $m | [20.1](/filings/0001437749-24-034539.md) | [16.0 d](/filings/0001437749-25-009139.md) | [7.0](/filings/0001437749-25-017173.md) | [11.1](/filings/0001437749-25-026526.md) | [10.4](/filings/0001437749-25-034871.md) | [9.0 d](/filings/0001437749-26-009285.md) | [0.0](/filings/0001437749-26-017437.md) | [0.0](/filings/0001437749-26-028004.md) | [8.4](/filings/0001437749-25-034871.md) | [6.6 d](/filings/0001437749-26-009285.md) | [0.0](/filings/0001437749-26-017437.md) | [0.0](/filings/0001437749-26-028004.md) |
| Gross profit | $m | [19.6](/filings/0001437749-24-034539.md) | [16.7 d](/filings/0001437749-25-009139.md) | [13.2](/filings/0001437749-25-017173.md) | [16.9](/filings/0001437749-25-026526.md) | [15.8](/filings/0001437749-25-034871.md) | [15.6 d](/filings/0001437749-26-009285.md) | [0.1](/filings/0001437749-26-017437.md) | [0.0](/filings/0001437749-26-028004.md) | [10.7](/filings/0001437749-25-034871.md) | [8.5 d](/filings/0001437749-26-009285.md) | [0.0](/filings/0001437749-26-017437.md) | [0.0](/filings/0001437749-26-028004.md) |
| Research and development | $m | [0.9](/filings/0001437749-24-034539.md) | [0.8 d](/filings/0001437749-25-009139.md) | [0.0](/filings/0001437749-24-017071.md) | [0.0](/filings/0001437749-24-025892.md) | [0.0](/filings/0001437749-24-034539.md) | [0.0 d](/filings/0001437749-25-009139.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(6.5)](/filings/0001437749-24-034539.md) | [(8.2) d](/filings/0001437749-25-009139.md) | [(5.3)](/filings/0001437749-25-017173.md) | [(3.2)](/filings/0001437749-25-026526.md) | [(1.7)](/filings/0001437749-25-034871.md) | [(1.6) d](/filings/0001437749-26-009285.md) | [(3.3)](/filings/0001437749-26-017437.md) | [(3.6)](/filings/0001437749-26-028004.md) | [(2.0)](/filings/0001437749-25-034871.md) | [(7.7) d](/filings/0001437749-26-009285.md) | [(3.2)](/filings/0001437749-26-017437.md) | [(4.0)](/filings/0001437749-26-028004.md) |
| Interest expense | $m | [0.5](/filings/0001437749-24-034539.md) | [0.5 d](/filings/0001437749-25-009139.md) | [0.4](/filings/0001437749-25-017173.md) | [0.3](/filings/0001437749-25-026526.md) | [0.3](/filings/0001437749-25-034871.md) | [0.3 d](/filings/0001437749-26-009285.md) | [0.2](/filings/0001437749-26-017437.md) | [0.3](/filings/0001437749-26-028004.md) | [0.3](/filings/0001437749-25-034871.md) | [0.2 d](/filings/0001437749-26-009285.md) | [0.2](/filings/0001437749-26-017437.md) | [0.3](/filings/0001437749-26-028004.md) |
| Income tax | $m | [0.1](/filings/0001437749-24-034539.md) | [(1.0) d](/filings/0001437749-25-009139.md) | [0.1](/filings/0001437749-25-017173.md) | [0.2](/filings/0001437749-25-026526.md) | [(0.2)](/filings/0001437749-25-034871.md) | [(0.1) d](/filings/0001437749-26-009285.md) | [0.0](/filings/0001437749-26-017437.md) | [0.0](/filings/0001437749-26-028004.md) | [0.0](/filings/0001437749-25-034871.md) | [(0.0) d](/filings/0001437749-26-009285.md) | [0.0](/filings/0001437749-26-017437.md) | [0.0](/filings/0001437749-26-028004.md) |
| Net income | $m | [(6.3)](/filings/0001437749-24-034539.md) | [(7.7) d](/filings/0001437749-25-009139.md) | [(5.2)](/filings/0001437749-25-017173.md) | [(3.6)](/filings/0001437749-25-026526.md) | [(1.8)](/filings/0001437749-25-034871.md) | [(1.3) d](/filings/0001437749-26-009285.md) | [(3.9)](/filings/0001437749-26-017437.md) | [(4.9)](/filings/0001437749-26-028004.md) | [(2.3)](/filings/0001437749-25-034871.md) | [(7.9) d](/filings/0001437749-26-009285.md) | [(6.1)](/filings/0001437749-26-017437.md) | [(0.5)](/filings/0001437749-26-028004.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | [(0.95)](/filings/0001437749-24-034539.md) | not reported | [(0.76)](/filings/0001437749-25-017173.md) | [(0.52)](/filings/0001437749-25-026526.md) | [(0.25)](/filings/0001437749-25-034871.md) | not reported | [(0.52)](/filings/0001437749-26-017437.md) | [(0.63)](/filings/0001437749-26-028004.md) | [(0.28)](/filings/0001437749-25-034871.md) | not reported | [(0.69)](/filings/0001437749-26-017437.md) | [(0.05)](/filings/0001437749-26-028004.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: not reported
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [28.0](/filings/0001437749-24-034539.md) | [20.0](/filings/0001437749-25-009139.md) | [17.5](/filings/0001437749-25-017173.md) | [20.3](/filings/0001437749-25-026526.md) | [16.1](/filings/0001437749-25-034871.md) | [18.0](/filings/0001437749-26-009285.md) | [14.3](/filings/0001437749-26-017437.md) | [10.5](/filings/0001437749-26-028004.md) | [7.6](/filings/0001437749-25-034871.md) | [4.9](/filings/0001437749-26-009285.md) | [2.3](/filings/0001437749-26-017437.md) | [2.5](/filings/0001437749-26-028004.md) |
| Current assets | $m | [68.7](/filings/0001437749-23-030994.md) | [49.6](/filings/0001437749-25-009139.md) | [43.6](/filings/0001437749-24-017071.md) | [48.2](/filings/0001437749-24-025892.md) | [40.9](/filings/0001437749-24-034539.md) | [38.7](/filings/0001437749-26-009285.md) | [39.4](/filings/0001437749-25-017173.md) | [35.3](/filings/0001437749-25-026526.md) | [30.4](/filings/0001437749-25-034871.md) | [28.5](/filings/0001437749-26-028004.md) | [21.2](/filings/0001437749-26-017437.md) | [23.3](/filings/0001437749-26-028004.md) |
| Total assets | $m | [82.0](/filings/0001437749-23-030994.md) | [61.9](/filings/0001437749-25-009139.md) | [55.7](/filings/0001437749-24-017071.md) | [59.9](/filings/0001437749-24-025892.md) | [52.1](/filings/0001437749-24-034539.md) | [49.5](/filings/0001437749-26-009285.md) | [49.8](/filings/0001437749-25-017173.md) | [45.4](/filings/0001437749-25-026526.md) | [40.1](/filings/0001437749-25-034871.md) | [29.6](/filings/0001437749-26-028004.md) | [22.2](/filings/0001437749-26-017437.md) | [23.5](/filings/0001437749-26-028004.md) |
| Current liabilities | $m | [38.6](/filings/0001437749-23-030994.md) | [25.4](/filings/0001437749-25-009139.md) | [22.3](/filings/0001437749-24-017071.md) | [28.7](/filings/0001437749-24-025892.md) | [21.3](/filings/0001437749-24-034539.md) | [19.3](/filings/0001437749-26-009285.md) | [22.6](/filings/0001437749-25-017173.md) | [20.9](/filings/0001437749-25-026526.md) | [17.3](/filings/0001437749-25-034871.md) | [14.1](/filings/0001437749-26-028004.md) | [12.5](/filings/0001437749-26-017437.md) | [10.9](/filings/0001437749-26-028004.md) |
| Total liabilities | $m | [40.1](/filings/0001437749-23-030994.md) | [25.8](/filings/0001437749-25-009139.md) | [22.7](/filings/0001437749-24-017071.md) | [29.0](/filings/0001437749-24-025892.md) | [21.5](/filings/0001437749-24-034539.md) | [19.5](/filings/0001437749-26-009285.md) | [22.8](/filings/0001437749-25-017173.md) | [21.1](/filings/0001437749-25-026526.md) | [17.5](/filings/0001437749-25-034871.md) | [14.4](/filings/0001437749-26-028004.md) | [12.7](/filings/0001437749-26-017437.md) | [10.9](/filings/0001437749-26-028004.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [41.9](/filings/0001437749-24-034539.md) | [36.0](/filings/0001437749-26-009285.md) | [33.0](/filings/0001437749-25-026526.md) | [30.9](/filings/0001437749-25-034871.md) | [30.6](/filings/0001437749-25-034871.md) | [30.0](/filings/0001437749-26-028004.md) | [27.0](/filings/0001437749-26-028004.md) | [24.3](/filings/0001437749-26-028004.md) | [22.6](/filings/0001437749-25-034871.md) | [15.2](/filings/0001437749-26-028004.md) | [9.5](/filings/0001437749-26-028004.md) | [12.6](/filings/0001437749-26-028004.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [399 d](/filings/0001437749-24-034539.md) | [(4,930) d](/filings/0001437749-25-009139.md) | [(6.0)](/filings/0001437749-25-017173.md) | [2,902 d](/filings/0001437749-25-026526.md) | [(722) d](/filings/0001437749-25-034871.md) | [(9.0) d](/filings/0001437749-26-009285.md) | [(3,868)](/filings/0001437749-26-017437.md) | [(4,419) d](/filings/0001437749-26-028004.md) | [(1,566) d](/filings/0001437749-25-034871.md) | [(1,042) d](/filings/0001437749-26-009285.md) | [(363)](/filings/0001437749-26-017437.md) | [438 d](/filings/0001437749-26-028004.md) |
| Capital expenditure | $k | [14.0 d](/filings/0001437749-24-034539.md) | [39.0 d](/filings/0001437749-25-009139.md) | [36.0](/filings/0001437749-25-017173.md) | [6.0 d](/filings/0001437749-25-026526.md) | [0.0 d](/filings/0001437749-25-034871.md) | [0.0 d](/filings/0001437749-26-009285.md) | [0.0](/filings/0001437749-26-017437.md) | [6.0 d](/filings/0001437749-26-028004.md) | [40.0 d](/filings/0001437749-25-034871.md) | [5.0 d](/filings/0001437749-26-009285.md) | [4.0](/filings/0001437749-26-017437.md) | [14.0 d](/filings/0001437749-26-028004.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q2 FY2021 (2021-06-30) | Q3 FY2021 (2021-09-30) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [29.5](/filings/0001564590-22-028487.md) | [35.4](/filings/0000950170-22-023937.md) | [55.1](/filings/0000950170-23-020586.md) | [63.9](/filings/0000950170-23-040550.md) | [64.6](/filings/0000950170-22-023937.md) | [76.7](/filings/0000950170-23-020586.md) | [77.6](/filings/0000950170-23-040550.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 17,966,910 at 2026-08-12, from the cover of the [10-Q filed 2026-08-14](/filings/0001437749-26-028004.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.